Autoimmunity

About
Our Company

Management

Board of Directors

Scientific Advisory Board

Partners

About TScan

TScan is a clinical-stage biotechnology company dedicated to changing lives by developing safe and effective T-cell therapies for patients.
Our Approach
Our Science

How We’re Different

Hematologic Malignancies

Solid Tumors

Autoimmunity

Our Approach

Our approach is based on the premise that conventional T cells provide the most effective way to fight cancer, and that by genetically reprogramming T cells with highly effective, naturally occurring T cell receptors (TCRs), we can harness the power of the human immune system to deliver life-changing therapies to patients.
Pipeline
Our Pipeline

Hematologic Malignancies Program

Solid Tumor Program

Pipeline

We are advancing a robust pipeline of TCR-T therapy candidates derived from our proprietary platform to treat patients with heme malignancies and solid tumors
Platform
TargetScan

ReceptorScan

SafetyScan

T-Integrate Cell Engineering

Platform

Our proprietary platform is designed to discover anti-cancer TCRs from patients with exceptional responses to immunotherapy.
Publications
Investors and Media
For Patients
Patient Overview

Hematologic Malignancies

Solid Tumors

Expanded Access Policy

For Patients

We are committed to bringing new immunotherapies to cancer patients.
Careers

Our Approach

Autoimmune disorders occur when the body’s immune system mistakenly attacks its own tissues and organs, causing inflammation and damage.

While primarily focused on oncology, we believe our TargetScan technology is well suited to identify unknown targets that cause T cell-driven autoimmune disorders. We have identified a set of indications in which T cells play a key role and are currently identifying targets and developing potential treatment options for these disorders.

In May 2023, Amgen (NASDAQ: AMGN) and TScan initiated a multi-year collaboration that utilizes TargetScan to identify the antigens recognized by T cells in patients with Crohn’s disease. Amgen may create therapeutics based on targets discovered by TScan and will retain all global development and commercial rights.